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costs in intraoperative changes of the surgical plan and reductions in unnecessary
surgery associated with the use of PV-MRI. Results from the previous study VALUE,
which showed that no patient with PV required additional imaging tests as part of
a Phase IV, confirm the results obtained in the present analysis (resulting in even
slightly lower cost than the total cost of diagnosis using PV-MRI).
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OBJECTIVES: Cervical cancer incidence in Serbia has been identified as one of the
highest in Europe, showing slow but steady increase during the last decade. De-
spite the National Programme for Prevention of Cervical Cancer that has recently
been established, an organised Pap screening is far from full implementation. This
study aims to assess the effectiveness and cost effectiveness of absolute adherence
to the proposed policy compared to the current practice. METHODS: A Markov
model simulating the natural history of cervical cancer was developed. Calibration
was performed using country specific data, sourcing incidence and mortality from
Serbian cancer registries. Accordingly, the screening algorithm incorporated in the
model was based on the local guidelines. We followed a hypothetical cohort of
100,000 15-year old girls until the end of their lifetime. Subsequently, the actual
cytological screening practice covering only 20% of the targeted population was
compared to a scenario of absolute adherence to the national screening pro-
gramme. A discount rate of 1.5% for health and 4% for cost outcomes was applied.
RESULTS: The natural history model showed that limited benefit is currently being
achieved from cytological screening. The hypothetical cohort analysis indicated
that absolute guidelines adherence would result in 422 deaths averted and an
incremental cost effectiveness ratio (ICER) of 3272 €/LYG. The ICER estimate did not
exceed the national annual GDP (3857 €/capita) - a commonly used informal
threshold. CONCLUSIONS: This research identified that full adherence to the
screening policy is very likely to be cost effective. In general, the low screening
coverage that has been observed appeared as the most serious obstacle to the
prevention of cervical cancer. The new methods in cervical cancer prevention,
however, such as HPV vaccination and HPV testing, require further pharmacoeco-
nomic assessment.
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OBJECTIVES: This study aimed to develop cost-effectiveness analysis of Soft Sili-
cone Wound-Contact Dressing (SS) versus Silver Sulphadiazine (SSD) in children
with partial-thickness scalds (PTS), under the perspective of Brazilian public
payers.METHODS: A literature search was conducted to gather efficacy data for SS
and SSD and identified one randomized controlled trial that compared median
time to 100% epithelialization (MTH) for SS and SSD. These data were used to
estimate clinical benefits in terms of “inpatient days avoided”. The model assumed
that SSD is the current practice in Brazilian public hospitals and patients are dis-
charged at the time their wound heals. Resource use was estimated through expert
panel, only direct medical costs were included in the analysis and unit costs were
obtained from Brazilian official price lists. RESULTS: The randomized trial ob-
served MTH of 10.5 and 27.6 days for SS and SSD, respectively (incremental effec-
tiveness of -17.1 days). Evidence from smaller observational studies have reported
intervals to SS change of up to 14 days, while SSD requires two changes per day.
Thus, the model estimated costs for the inpatient period assuming one dressing
change for SS and 28 changes for SSD. The cost per dressing change was estimated
as 33BRL for SS and 23BRL for SSD and the overall treatment costs were 1,261BRL
and 23BRL. SS-related incremental costs were -1228BRL indicating a cost-saving
profile. Benefits in terms of reduction in length of stay were not accounted in the
base case scenario. If average public hospital daily charges were included in the
cost estimation, savings would reach -2209BRL. CONCLUSIONS: SS dressing has
shown higher efficacy when compared to SSD, with fewer overall costs. The signif-
icant reduction in the median time to healing offset the higher unit cost by lower-
ing the number of required changes and the total length of stay.
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OBJECTIVES: A new ambulatory electrocardiogram (loop recorder) has been intro-
duced in Canada to detect arrhythmias, overcoming issues of previous recorders
with its capability of automatically detecting/sending electrocardiograph data and
simultaneously patient activation of device during symptoms. The loop recorder is
expected to have a higher diagnostic yield due to its recording capabilities and
longer test period (14days) however the cost is greater than the standard of care
(Holter). Cost-effectiveness was estimated for Holter versus the loop recorder for
diagnosing paroxysmal or persistent atrial fibrillation in primary physician care in
Ontario, Canada, from a health payer‘s perspective. METHODS: A probabilistic
decision analytic model was constructed to estimate cost, number of cases cor-
rectly detected, and number of strokes averted due to correct detection and treat-
ment over a 19 month period. Direct medical costs included diagnostic testing,
treatment of atrial fibrillation, prevention of stroke, and treatment of stroke. Costs
were expressed in 2011 Canadian dollars. One-way, multi-way and probabilistic
analyses of uncertainty were conducted. Model inputs were from various sources
including primary data, published literature and expert opinion.RESULTS:Average
cost was estimated at $490 for Holter, and $612 for loop recorder. Average cases of
atrial fibrillation correctly detected were 0.032 for Holter, and 0.058 for loop re-
corder. Average number of strokes averted were 0.010 for Holter and 0.018 for loop
recorder. The probabilistic mean incremental cost-effectiveness ratio of loop re-
corder versus Holter was $2430 per additional case correctly detected and $698 per
additional stroke averted. At a $20,000 willingness-to-pay threshold the probability
of the loop recorder being cost effective for cases detected and strokes averted were
95.5% and 60.4% respectively. Cases detected and strokes averted were 99.3% and
92% respectively for a willingness-to-pay of $50,000. CONCLUSIONS: Cost-effec-
tiveness analysis favours the new loop recorder compared to Holter.
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OBJECTIVES: The Corail™ Hip System, a hydroxyapatite coated cementless im-
plant, has demonstrated its high efficacy and safety for primary total hip arthro-
plasty (THA) for over 20 years. The objective of this work was to evaluate the
cost-effectiveness of the Corail™ Hip System in comparison with other cementless
hip designs (standard) in Spain. METHODS: An analytical decision-making model
was constructed as a Markov model for patients who were candidates to THA. The
study perspective was from the viewpoint of the Spanish National Health System
(NHS). Time horizons included in the model were 10 or 20 years and lifetime.
Healthcare costs associated with the compared interventions and their conse-
quences were expressed in euro 2011. Data came from a review of the literature and
was validated by local clinical experts. A discount rate of 3% was applied on costs
and efficacy data. RESULTS: The use of the Corail™ Hip System for THA compared
with the standard resulted in €4317 per revision avoided and €5812 per QALY
gained considering a time horizon of 10 years. The result was dominant in favour of
Corail™ when a time horizon of 20 years or lifetime was considered for all the
scores. Corail™ provided a gain of 0.075 QALY and saved €279 versus the standard
(lifetime). There were no significant differences between sexes. In the sensitivity
analysis was built the best scenario for Corail™ including the worse efficacy data
available for the standard and Corail™ resulted in a gain of 0.388 QALY and saved
€2226 (lifetime). The probabilistic sensitivity analysis showed that Corail™ was
cost-effective in 76% of cases (threshold of €30,000/QALY). CONCLUSIONS: Prelim-
inary results showed that the Corail™ Hip System is a cost-effective option in THA
compared with the rest of cementless hip trademarks available in Spain.
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OBJECTIVES: To compare the costs and effectiveness of the EX-PRESS glaucoma
filtration device (Alcon Inc, TX) to trabeculectomy, 5 years after surgery, in primary
open angle glaucoma (POAG). METHODS: Seventy-eight patients with POAG un-
controlled despite maximally-tolerated medical therapies were randomized to re-
ceive either the EX-PRESS or undergo a trabeculectomy, realized by a single sur-
geon. Outcomes captured over 5 years included intraocular pressure (IOP a
surrogate endpoint of glaucoma progression), use of IOP lowering medications and
additional eye surgeries. The economic perspective was the one of the Dutch Na-
tional Health System. Patients were considered a success if they had an IOP less
than or equal to the success thresholds of 15 or 18 mmHg, without IOP lowering
medications, and without having undergone further glaucoma surgery. Time to
failure was analyzed using a log rank test. Costs were discounted at a 4% rate.
EX-PRESS cost was not included. RESULTS: The 5-year failure rate was 41% for
EX-PRESS versus 69% for trabeculectomy (P0.005) using an 18 mmHg IOP target
and 46% versus 77% (P0.001) for 15 mmHg. EX-PRESS patients were less likely to
use medications, and among the medically treated patients, required fewer drugs.
EX-PRESS eyes required less needling (2 vs 5) and less cataract surgery (5 vs. 8).
Without discounting, drug savings with EX-PRESS equaled €333.86 and €107.79 for
eye surgery /laser, a total of €441.65. With a 4% discounting, the figures became
€310.45, €132.78 and €443.23, respectively. CONCLUSIONS: At 5 years after surgery,
EX-PRESS demonstrated that it better controls IOP than trabeculectomy, resulting
in savings in both IOP lowering drugs and eye surgeries. Economic benefits of the
better IOP control (less disease progression, i.e. a better vision) and saving accord-
ing to a lifelong time horizon will be estimated in future modelling exercises.
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OBJECTIVES: EX-PRESS glaucoma filtration device (Alcon Inc, TX) is an alternative
treatment to trabeculectomy, a surgery realized in advanced primary open angle
glaucoma (POAG). This analysis reports the incremental cost and benefits of
EX-PRESS. METHODS: Patients with POAG uncontrolled by maximally-tolerated
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medical therapies were randomized to receive either the EX-PRESS or a trabeculec-
tomy. Clinical outcomes included intraocular pressure (IOP), use of IOP lowering
medications and post-operative eye surgeries. The study follow-up was 5 years.
The economic perspective was the one of the French society. EX-PRESS cost was
not included. Patients were considered a success if they had an IOP less than or
equal to the success thresholds of 15 or 18 mmHg, without IOP lowering medica-
tions, and without having undergone further glaucoma surgery. Time to failure
was analyzed using a log rank test. Costs were discounted at a 3% rate. RESULTS: 78
patients were analyzed, 39 in each arm. EX-PRESS eyes had better IOP control at 1
(12.0 vs 13.9 mmHg; P0.02), 2 (11.9 vs 13.8 mmHg; P0.01) and 3 years (12.0 vs 13.5
mmHg; P0.04). The five-year failure rate was 41% for EX-PRESS versus 69% for
trabeculectomy (P0.005) using an 18 mmHg IOP target and 46% versus 77%
(P0.001) for 15 mmHg. At year 5, 41.0% of the EX-PRESS patients had an IOP
lowering drug prescription versus 53.9% for the trabeculectomy patients. EX-PRESS
patients received 0.85 IOP lowering medications versus 1.10 in the trabeculectomy
group. EX-PRESS patients required less needling (2 versus 5) and had fewer cataract
surgeries (5 versus 8). Without discounting, drug savings with EX-PRESS equaled
€277.00, €331.02 as a total. With a 3% discounting, the figures became €260.00 and
€342.97, respectively. CONCLUSIONS: At 5 years after surgery, EX-PRESS demon-
strated that it better controls IOP than trabeculectomy, resulting in post-operative
savings.
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OBJECTIVES: ST2 is a blood test that accurately risk stratifies patients with heart
failure (HF). This enables physicians to select high risk patients for intensive dis-
ease management (DM) programs. We evaluated the cost-effectiveness of ST2 in
patients discharged from hospital after an acute heart failure event.METHODS:We
developed a decision-analytic model to explore the 30-day mortality and cost out-
comes. A horizon of 30 days was used as a recognized hospital quality metric. We
compared two clinical scenarios: 1) HF patients did not enter DM programs; 2) only
patients with ST235 ng/ml entered DM programs. The clinical data came from the
Basel study, a prospective, blinded study of 591 HF subjects. We modeled the mor-
tality, the hypothetical reimbursement of ST2 testing, costs of DM and hospitaliza-
tions. A US health care system perspective was taken. A range of sensitivity anal-
yses and scenario analyses were performed. RESULTS: We simulated a cohort of
patients with a mean age of 78 years old over the 30-day period post discharge.
During that period there was 11.8% mortality and 20.1% all cause re-hospitalization
rates. We assumed a 26% reduction in mortality and a 21% reduction in re-hospi-
talization from intensive DM based on a peer-reviewed meta-analysis. The base
case showed that the ST2 strategy reduces lost life years by 0.217 with cost saving
of $1079 per tested patient when compared to no DM. Sensitivity analyses suggest
that the model is most sensitive to the cost of re-hospitalization and the cost and
effectiveness of the intensive DM program. CONCLUSIONS: Under a variety of
scenarios, prediction of 30-day HF risk with ST2, in order to select high risk patients
for enrollment into intensive DM programs, reduces mortality and is cost saving.
PMD39
COST EFFECTIVENESS ANALYSIS OF INTRATHECAL BACLOFEN THERAPY (
TRICUMED™) VERSUS MEDICAL TREATMENTS FOR SEVERE SPASTICITY IN
TURKEY
Malhan S1, Oksuz E2, Ozsezer Y3
1Baskent University, Ankara, Turkey, 2Baskent University, Ankara, Turkey, 3Neuromodulation
Group, Ýstanbul, Turkey
OBJECTIVES: The objective was from a Turkish perspective to analyse the incre-
mental cost-effectiveness of Intrathecal baclofen therapy ( Tricumed™) compared
with medical treatment in adults for severe spasticity in Turkey. METHODS: We
compared the costs and health effects of intrathecal baclofen therapy with stan-
dard treatment only, from the health care perspective for a 1-year period. Health
effects were expressed in terms of an “ashworth score” as a year. The ashworth
score data was collected from the literature for both Intrathecal Baclofen Therapy
and medical treatment for severe spasticity. The cost of the treatments were cal-
culated based on the treatment guidelines for Turkish patient from the Turkish
health care payer’s perspectives. RESULTS: The annual average cost of Intrathecal
Baclofen Therapy per patient has been estimated to be €10357,27. On the other
hand, the yearly average cost of medical treatment per patient has been found as
€6080,16. The incremental cost effectiveness ratio (ICER) for Intrathecal Baclofen
Therapy versus Medical Treatment for severe spasticity analysed as 89,33€ per
“ashworth score”. CONCLUSIONS: Intrathecal Baclofen Therapy is a cost-effective
technology for the severe spasticity patients compared to the medical treatment
for severe spasticity in Turkey.
PMD40
COST EFFECTIVENESS OF FRACTIONAL FLOW RESERVE MEASUREMENT IN
MULTIVESSEL CORONARY ARTERY DISEASE IN BELGIUM AND FRANCE
Bornschein B1, Arvandi M1, Gothe R1, Rioufol G2, De bruyne B3, De pouvourville G4,
Desmet W5, Lefevre T6, Fearon WF7, Pijls NHJ8, Siebert U9
1UMIT - University for Health Sciences, Medical Informatics and Technology, Hall i. Tirol,
Austria, 2Cardiovascular hospital - Hospices Civils de Lyon, Lyon, France, 3OLV-Clinic-Aalst,
Cardiovascular Center Aalst, Aalst, Belgium, 4ESSEC Business School, Cergy, France, 5University
Hospitals Leuven, Leuven, Belgium, 6Hopital Privé Jacques Cartier, Massy, France, 7Stanford
University Medical Center, Stanford, CA, USA, 8Catharina Hospital, Eindhoven, The Netherlands,
9UMIT/Oncotyrol/Harvard University, Hall i.T.;Innsbruck, Tyrol, Austria
OBJECTIVES: The FAME Study is an international multicenter randomized clinical
trial (n1,005), which demonstrated a significant improvement in health outcomes
for patients with multivessel coronary artery disease undergoing percutaneous
coronary intervention (PCI) guided by fractional flow reserve measurement (FFR)
compared to PCI guided by angiography alone. We performed a cost-effectiveness
analysis along the FAME trial to estimate the cost effectiveness of FFR in France and
Belgium and compared the results with those of other European countries.
METHODS: We used original patient-level data of the FAME study (Tonino et al.,
NEJM 2009) to estimate resource consumption, which was valued using prices from
French and Belgian price lists and DRG catalogues (2010 values). Utilities were
measured with EQ-5D based on French time trade-off and Torrance-transformed
Belgian visual analogue scale (VAS) weights. We adopted a societal perspective and
a one-year time horizon (i.e., follow-up of the FAME Study). Variability was exam-
ined using one-way sensitivity analysis and bootstrap resampling (n5000). Re-
sults are expressed in incremental costs (EUR) and incremental QALYs. RESULTS:
In both countries, FFR slightly improved QALYs (p0.05) at significantly lower costs
(p0.05). Cost savings reached approximately 900 EUR/patient for both countries.
For both countries, bootstrap analysis showed that FFR was cost saving in50% of
all bootstrap samples and cost effective in 90% when using a cost-effectiveness
threshold of 50,000 EUR/QALY. The most influential cost components were prices
for DES and FFR pressure wires. Cost-savings in France and Belgium are higher than
recently presented results for Germany, the UK and Italy, where FFR is cost saving
with savings ranging from 300-600 EUR/patient. CONCLUSIONS: In the context of
the health care systems of Belgium and France, FFR-guided PCI is cost saving (dom-
inant) in patients with multivessel coronary artery disease. These results are ro-
bust and in line with those of other European countries.
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OBJECTIVES: An ongoing 2-year local prospective study to compare clinical, hu-
manistic and economic outcomes of Drug Eluting Stents (DES) and Bare Metal
Stents (BMS). METHODS: All patients receiving DES or BMS placement in Prince of
Wales Hospital in Hong Kong within the period of September 2009 to March 2010
were recruited and followed for 12 months. Clinical outcome was measured by
occurrence of major adverse cardiac events (MACE). EQ-5D questionnaire, with
visual analog scale (VAS), was used to assess patients’ health-related quality of life.
The questionnaire was administered by patients before procedure, at 6 month and
12 month. Cost of index procedure and follow-up were recorded and cost per QALY
of DES over BMS was used to evaluate cost-effectiveness of DES. Subgroup analysis
was performed on patients with diabetes mellitus (DM). RESULTS: 325 patients
were enrolled (n210 for DES and n115 for BMS), with balanced baseline charac-
teristics. MACE was significantly less common in DES group (n10, 4.8% vs n14,
12.2%; OR0.361, 95% Cl0.155 to 0.841). The increase in utility score at 12 month
was 0.22 for DES group and 0.17 for BMS group (p0.294). Aggregate 12-month cost
was higher in DES group (HK$110,640 68,706 vs HK$99,802 93,420; p0.235). Cost per
QALY gained for DES was HK$184,564. Subgroup analysis showed that cost per
QALY was HK$15,303 in DM patients. Subsidizing DM patients to use DES, instead
of BMS, could save up to HK$6,370,000 annually for Hospital Authority. (1US$ 7.8
HK$) CONCLUSIONS: DES was shown to be superior to BMS in clinical outcome.
Even with higher procedural cost in DES group, the lower follow-up cost resulted in
gradually smaller difference in aggregate cost. DES was more cost-effective than
BMS, especially in DM patients. Subsidizing DM patients to use DES would be cost-
saving and lead to better clinical outcome.
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OBJECTIVES: Neutropaenia, a chemotherapy-related adverse event, is graded in
terms of severity and can have different relative effects on health and resource use.
For advanced colorectal cancer (CRC) patients on irinotecan-based chemotherapy,
UGT1A1 testing can stratify populations into different risk groups to potentially
reduce the incidence of febrile neutropaenia, which may also impact on healthcare
resources. High-risk patients can be prescribed lower irinotecan doses to reduce
febrile neutropaenia. Two previous economic evaluations of UGT1A1 testing fo-
cussed on reducing grade 3&4 neutropaenia. This study aimed to assess the cost-
effectiveness of UGT1A1 testing to reduce the incidence of irinotecan-related fe-
brile neutropaenia. METHODS: An economic model of UGT1A1 testing to predict
febrile neutropaenia compared to standard care was developed over a lifetime
horizon from the UK NHS perspective. Treatment pathways were informed by a
national survey of CRC experts (n44). Model inputs were identified from: a micro-
costing observational study (n48 patients), CRC expert (n55) elicitation and pub-
lished literature. RESULTS: UGT1A1 testing was cost-saving and resulted in lower
incidence of febrile neutropaenia. For a cohort of 100 patients, the test was esti-
mated to save £17,700, avoid 0.4 febrile neutropaenic episodes, gain 0.006 life-years
and 0.007 QALYs. The likelihood that the test was cost-effective was 94% at a
threshold of £25,000 per QALY gained. Sensitivity analysis (probabilistic and one-
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